Dissecting super-enhancer heterogeneity: time to re-examine cancer subtypes?

Tan Wu; Hao Huang; Xin Wang

doi:10.1016/j.tig.2022.06.006

Dissecting super-enhancer heterogeneity: time to re-examine cancer subtypes?

Trends Genet. 2022 Dec;38(12):1199-1203. doi: 10.1016/j.tig.2022.06.006. Epub 2022 Jul 5.

Authors

Tan Wu¹, Hao Huang², Xin Wang³

Affiliations

¹ Department of Surgery, The Chinese University of Hong Kong, Hong Kong, SAR, China; Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, SAR, China.
² State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
³ Department of Surgery, The Chinese University of Hong Kong, Hong Kong, SAR, China. Electronic address: xinwang@cuhk.edu.hk.

PMID: 35803787
DOI: 10.1016/j.tig.2022.06.006

Abstract

The heterogeneity of transcriptional regulations by super-enhancers (SEs) is poorly understood in human cancers. Herein, we summarize a bioinformatics workflow for genome-wide SE profiling and identification of subtype-specific SEs and regulatory networks. Dissecting SE heterogeneity provides new insights into cancer biology and alternative therapeutic strategies for cancer precision medicine.

Keywords: cancer subtype; heterogeneity; multi-omics; regulatory network; super-enhancer; transcription regulation.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Computational Biology
Enhancer Elements, Genetic / genetics
Gene Expression Regulation
Humans
Neoplasms* / genetics
Regulatory Sequences, Nucleic Acid*